

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 1, 2025

NCI-H2030

RRID:CVCL_1517

Type: Cell Line

Proper Citation

(RRID:CVCL_1517)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1517

Proper Citation: (RRID:CVCL_1517)

Sex: Male

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: NCI-H2030

Synonyms: H2030, H-2030, NCIH2030

Cross References: BTO:BTO_0006438, CLO:CLO_0008041, EFO:EFO_0002274, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5914, BioGRID_ORCS_Cell_line:534, BioSample:SAMN03471413, BioSample:SAMN10988239, cancercellines:CVCL_1517, Cell_Model_Passport:SIDM00715, ChEMBL-

Cells:CHEMBL3308769, ChEMBL-Targets:CHEMBL1075530, Cosmic:722045, Cosmic:903611, Cosmic:1146897, Cosmic:1609520, Cosmic:1995553, Cosmic-CLP:722045, DepMap:ACH-000521, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:722045, GEO:GSM206483, GEO:GSM274747, GEO:GSM274748, GEO:GSM434332, GEO:GSM784272, GEO:GSM794344, GEO:GSM887397, GEO:GSM888475, GEO:GSM1374717, GEO:GSM1670208, IARC_TP53:21552, IGRhCellID:NCIH2030, LiGeA:CCLE_404, LINCS_LDP:LCL-1648, PharmacDB:NCIH2030_1058_2019, PRIDE:PXD030304, Progenetix:CVCL_1517, PubChem_Cell_line:CVCL_1517, Wikidata:Q54907906

ID: CVCL_1517

Record Creation Time: 20250131T201500+0000

Record Last Update: 20250131T203139+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2030.

No alerts have been found for NCI-H2030.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Pulawska-Moon K, et al. (2024) Novel ectopic expression of zona pellucida 3 glycoprotein in lung cancer promotes tumor growth. International journal of cancer.

Thatikonda V, et al. (2024) Genetic dependencies associated with transcription factor activities in human cancer cell lines. Cell reports, 43(5), 114175.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. International journal of cancer, 154(6), 1029.

Ye F, et al. (2023) TGF β Antagonizes IFN γ -Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma. Cancer research, 83(13), 2262.

Cheung AH, et al. (2023) MLK4 promotes glucose metabolism in lung adenocarcinoma

through CREB-mediated activation of phosphoenolpyruvate carboxykinase and is regulated by KLF5. *Oncogenesis*, 12(1), 35.

Sanidas I, et al. (2022) Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression. *Molecular cell*, 82(18), 3333.

Kitajima S, et al. (2022) MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. *Cancer cell*, 40(10), 1128.

Kanne J, et al. (2021) Pericentromeric Satellite III transcripts induce etoposide resistance. *Cell death & disease*, 12(6), 530.

Santana-Codina N, et al. (2020) Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics. *Cell reports*, 30(13), 4584.

Guerra SL, et al. (2020) A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. *Cancer cell*, 37(5), 705.

Cheng CC, et al. (2020) Sperm-specific COX6B2 enhances oxidative phosphorylation, proliferation, and survival in human lung adenocarcinoma. *eLife*, 9.

LeBoeuf SE, et al. (2020) Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids. *Cell metabolism*, 31(2), 339.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.

Takahashi N, et al. (2020) 3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis. *Molecular cell*, 80(5), 828.

Harris IS, et al. (2019) Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. *Cell metabolism*, 29(5), 1166.

Sulahian R, et al. (2019) Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. *Cell reports*, 29(1), 118.

Janes MR, et al. (2018) Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. *Cell*, 172(3), 578.

Kitajima S, et al. (2018) Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. *Cancer cell*, 34(3), 439.